Text Size

Use of Acetyl Salicylic Acid and Terbutalin in Assisted Reproductive Techniques (ART)

This study has been completed.
Sponsor:
Information provided by:
Sykehuset Telemark
ClinicalTrials.gov Identifier:
NCT00518141
First received: August 17, 2007
Last updated: July 20, 2011
Last verified: July 2011
History of Changes
  Purpose

This study aims to determine the possible effects of Acetyl Salicylic Acid (ASA) and Terbutalin on ART treatment.


Condition Intervention
Reproductive Techniques, Assisted
 Drug: Acetyl Salicylic Acid and Terbutalin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Use of Acetylsalicylic Acid and Terbutalin in ART

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Sykehuset Telemark:

Primary Outcome Measures:
  • Pregnancy [ Time Frame: 7 weeks ] [ Designated as safety issue: No ]

Enrollment: 300
Study Start Date: March 2006
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
FER
 Drug: Acetyl Salicylic Acid and Terbutalin
ASA 75 mg, Terbutalin 5mg
No Intervention: 2
FER
Experimental: 3
SET
 Drug: Acetyl Salicylic Acid and Terbutalin
ASA 75 mg, Terbutalin 5mg
No Intervention: 4
SET
Experimental: 5
DET
 Drug: Acetyl Salicylic Acid and Terbutalin
ASA 75 mg, Terbutalin 5mg
No Intervention: 6
DET

Detailed Description:

This study aims to determine the possible effects of ASA and Terbutalin on ART treatment.

  Eligibility

Ages Eligible for Study:   18 Years to 39 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Infertile women below 39 years of age

Exclusion Criteria:

  • Women who may react allergically to the drugs administered
  • Women with hyperthyroid or IDDM
  • Women who do not want to participate in the study
  • Women who are unable to give informed, written consent.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00518141

Locations
Norway
STHF, Kvinneklinikken, Fertilitetsklinikken Sor
Porsgrunn, Telemark, Norway, 3901
Sponsors and Collaborators
Sykehuset Telemark
Investigators
Principal Investigator: Jarl A Kahn, Dr. med STHF, Kvinneklinikken, Fertilitetsklinikken Sor
  More Information

No publications provided

Responsible Party: Jarl Kahn, Fertilitetsklinikken Sør
ClinicalTrials.gov Identifier: NCT00518141     History of Changes
Other Study ID Numbers: S-06085 (REK)
Study First Received: August 17, 2007
Last Updated: July 20, 2011
Health Authority: Norway:National Committee for Medical and Health Research Ethics

Additional relevant MeSH terms:
Aspirin
Salicylates
Salicylic Acid
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Fibrinolytic Agents
 Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents
Hematologic Agents
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics
Central Nervous System Agents
Anti-Infective Agents
Antifungal Agents
Keratolytic Agents
Dermatologic Agents

ClinicalTrials.gov processed this record on May 16, 2013